In a phase 2 study (NCT01735604) of anti-CD20 CAR-T therapy, the ORR was 81.8% (CR 54.5%).430 In a phase 1 trial (NCT02315612), anti-CD22 CAR-T cells were evaluated in patients with B-cell malignancies resistant to CD19 CAR-T cells and showed a CR rate of 73%, with a median remission duration of 6 months.431 A phase 1 trial (NCT01306146) of anti-CD30 CAR-T cells showed a CR rate of 28.6% in relapsed HL and a CR rate of 50% in ALCL.432. Here, TNFRSF8 is linked to Hodgkins lymphoma.